Search > Childhood Obesity
45 Participants NeededMy employer runs this trial

Maridebart Cafraglutide for Obesity

Recruiting at 2 trial locations
AC
Overseen ByAmgen Call Center
Age: 18+
Sex: Female
Trial Phase: Phase 1
Sponsor: Amgen
Must not be taking: Hormone therapy, GLP-1 agents
Disqualifiers: Diabetes, Pancreatitis, Cardiovascular disease, Cancer, Thyroid disorders, others
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.

Who Is on the Research Team?

M

MD

Principal Investigator

Amgen

Are You a Good Fit for This Trial?

Inclusion Criteria

Body weight must be stable, with less than 5 kg self-reported change in the 3 months before screening.
Participants must not have changed their diet or started a nutritional lifestyle modification program within 3 months before screening.
Other inclusion criteria may apply.
See 2 more

Exclusion Criteria

Other exclusion criteria may apply.
I have a history of certain thyroid cancers or uncontrolled thyroid disease.
I do not have allergies or intolerances to maridebart cafraglutide, ethinyl estradiol, or orgestimate.
See 20 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive COC orally and maridebart cafraglutide subcutaneously to assess pharmacokinetics

6-8 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Maridebart Cafraglutide

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: COC + Maridebart CafraglutideExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Amgen

Lead Sponsor

Trials
1,508
Recruited
1,433,000+
Founded
1980
Headquarters
Thousand Oaks, USA
Known For
Human Therapeutics
Top Products
Enbrel, Prolia, Neulasta, Otezla
Robert A. Bradway profile image

Robert A. Bradway

Amgen

Chief Executive Officer since 2012

MBA from Harvard Business School

Paul Burton profile image

Paul Burton

Amgen

Chief Medical Officer since 2023

MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.